MARIA RAIMUNDO

 .

Um grão de prevenção 

vale ouro de reação

A ɢᴇɴᴇ́ᴛɪᴄᴀ ᴛᴇᴍ ᴏ ᴘᴏᴛᴇɴᴄɪᴀʟ ᴅᴇ ᴍᴇʟʜᴏʀᴀʀ ᴀ ᴇғɪᴄɪᴇ̂ɴᴄɪᴀ﹐ ᴀᴄᴇssɪʙɪʟɪᴅᴀᴅᴇ﹐ sᴜsᴛᴇɴᴛᴀʙɪʟɪᴅᴀᴅᴇ ᴇ ʀᴇsɪʟɪᴇ̂ɴᴄɪᴀ ᴅᴏs sɪsᴛᴇᴍᴀs ᴅᴇ sᴀᴜ́ᴅᴇ.

𝓐𝓹𝓮𝓼𝓪𝓻 𝓭𝓪 𝓹𝓪𝓷𝓭𝓮𝓶𝓲𝓪 𝓽𝓮𝓻 𝓽𝓻𝓪𝔃𝓲𝓭𝓸 𝓭𝓮𝓼𝓪𝓯𝓲𝓸𝓼 𝓼𝓮𝓶 𝓹𝓻𝓮𝓬𝓮𝓭𝓮𝓷𝓽𝓮𝓼, 𝓸𝓼 𝓼𝓲𝓼𝓽𝓮𝓶𝓪𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓺𝓾𝓮 𝓳𝓪́ 𝓹𝓻𝓲𝓸𝓻𝓲𝓽𝓲𝔃𝓪𝓿𝓪𝓶 𝓮𝓼𝓽𝓻𝓪𝓽𝓮́𝓰𝓲𝓪𝓼 𝓬𝓮𝓷𝓽𝓻𝓪𝓭𝓪𝓼 𝓮𝓶 𝓭𝓪𝓭𝓸𝓼 𝓮 𝓹𝓪𝓬𝓲𝓮𝓷𝓽𝓮𝓼 𝓮𝓼𝓽𝓪𝓿𝓪𝓶 𝓶𝓪𝓲𝓼 𝓹𝓻𝓮𝓹𝓪𝓻𝓪𝓭𝓸𝓼 𝓹𝓪𝓻𝓪 𝓻𝓮𝓼𝓹𝓸𝓷𝓭𝓮𝓻 𝓪𝓸 𝓼𝓾𝓻𝓽𝓸. 𝓛𝓸𝓰𝓸, 𝓬𝓸𝓷𝓼𝓮𝓰𝓾𝓲𝓻𝓪𝓶 𝓲𝓻 𝓪𝓭𝓪𝓹𝓽𝓪𝓷𝓭𝓸 𝓸 𝓪𝓽𝓮𝓷𝓭𝓲𝓶𝓮𝓷𝓽𝓸 𝓪𝓸 𝓹𝓪𝓬𝓲𝓮𝓷𝓽𝓮 𝓮 𝓸 𝓹𝓵𝓪𝓷𝓮𝓪𝓶𝓮𝓷𝓽𝓸 𝓭𝓮 𝓮𝓶𝓮𝓻𝓰𝓮̂𝓷𝓬𝓲𝓪 𝓭𝓮 𝓪𝓬𝓸𝓻𝓭𝓸 𝓬𝓸𝓶 𝓮𝓼𝓼𝓪𝓼 𝓶𝓾𝓭𝓪𝓷𝓬̧𝓪𝓼 𝓮 𝓭𝓮 𝓪𝓬𝓸𝓻𝓭𝓸 𝓬𝓸𝓶 𝓪 𝓲𝓭𝓮𝓷𝓽𝓲𝓯𝓲𝓬𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓹𝓪𝓬𝓲𝓮𝓷𝓽𝓮𝓼 𝓬𝓸𝓶 𝓶𝓪𝓲𝓸𝓻 𝓻𝓲𝓼𝓬𝓸 𝓭𝓮 𝓬𝓸𝓷𝓽𝓻𝓪𝓲𝓻 𝓒𝓸𝓿𝓲𝓭-𝟏𝟗. 𝓐𝓫𝓻𝓪𝓬̧𝓪𝓻 𝓸𝓼 𝓪𝓿𝓪𝓷𝓬̧𝓸𝓼 𝓷𝓪 𝓮𝓼𝓽𝓻𝓪𝓽𝓲𝓯𝓲𝓬𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓻𝓲𝓼𝓬𝓸 𝓭𝓮 𝓹𝓸𝓹𝓾𝓵𝓪𝓬̧𝓸̃𝓮𝓼 𝓮 𝓷𝓪 𝓿𝓲𝓰𝓲𝓵𝓪̂𝓷𝓬𝓲𝓪 𝓭𝓮𝓼𝓼𝓮 𝓻𝓲𝓼𝓬𝓸, 𝓹𝓮𝓻𝓶𝓲𝓽𝓮-𝓷𝓸𝓼 𝓮𝓼𝓽𝓪𝓻 𝓶𝓪𝓲𝓼 𝓪𝓹𝓽𝓸𝓼 𝓷𝓪 𝓹𝓻𝓮𝓿𝓮𝓷𝓬̧𝓪̃𝓸 𝓭𝓮 𝓭𝓸𝓮𝓷𝓬̧𝓪 𝓮 𝓹𝓻𝓸𝓶𝓸𝓬̧𝓪̃𝓸 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮, 𝓮𝓵𝓮𝓶𝓮𝓷𝓽𝓸𝓼 𝓮𝓼𝓽𝓮𝓼 𝓺𝓾𝓮 𝓼𝓪̃𝓸 𝓫𝓪𝓼𝓲𝓵𝓪𝓻𝓮𝓼 𝓷𝓪 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓾́𝓫𝓵𝓲𝓬𝓪 𝓮 𝓷𝓪 𝓼𝓾𝓼𝓽𝓮𝓷𝓽𝓪𝓫𝓲𝓵𝓲𝓭𝓪𝓭𝓮 𝓭𝓸 𝓼𝓲𝓼𝓽𝓮𝓶𝓪 𝓷𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮. 𝓐 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓹𝓮𝓻𝓶𝓲𝓽𝓮 𝓹𝓮𝓻𝓬𝓮𝓫𝓮𝓻 𝓶𝓮𝓵𝓱𝓸𝓻 𝓬𝓸𝓻𝓻𝓮𝓵𝓪𝓬̧𝓸̃𝓮𝓼 𝓮 𝓻𝓲𝓼𝓬𝓸 𝓭𝓮 𝓭𝓸𝓮𝓷𝓬̧𝓪𝓼, 𝓹𝓪𝓭𝓻𝓸̃𝓮𝓼 𝓭𝓮 𝓰𝓻𝓾𝓹𝓸𝓼 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓲𝓼 𝓭𝓮 𝓶𝓸𝓭𝓸 𝓪 𝓪𝓿𝓪𝓵𝓲𝓪𝓻 𝓪 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓾́𝓫𝓵𝓲𝓬𝓪 𝓭𝓮 𝓶𝓸𝓭𝓸 𝓰𝓮𝓻𝓪𝓵. 𝓢𝓪̃𝓸 𝓷𝓮𝓬𝓮𝓼𝓼𝓪́𝓻𝓲𝓪𝓼 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪𝓼 𝓪 𝓷𝓲́𝓿𝓮𝓵 𝓭𝓪 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓹𝓪𝓻𝓪 𝓹𝓻𝓮𝓬𝓪𝓿𝓮𝓻 𝓷𝓸𝓿𝓪𝓼 𝓲𝓷𝓬𝓲𝓭𝓮̂𝓷𝓬𝓲𝓪𝓼 𝓭𝓮 𝓻𝓲𝓼𝓬𝓸 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓾́𝓫𝓵𝓲𝓬𝓪, 𝓹𝓪𝓻𝓪 𝓮𝓼𝓽𝓻𝓪𝓽𝓲𝓯𝓲𝓬𝓪𝓻 𝓸 𝓻𝓲𝓼𝓬𝓸 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓮 𝓹𝓪𝓻𝓪 𝓹𝓻𝓸𝓽𝓮𝓰𝓮𝓻 𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓯𝓸𝓻𝓶𝓪 𝓹𝓻𝓸𝓪𝓽𝓲𝓿𝓪. 𝓐 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓽𝓮𝓶 𝓸 𝓹𝓸𝓽𝓮𝓷𝓬𝓲𝓪𝓵 𝓭𝓮 𝓻𝓮𝓿𝓸𝓵𝓾𝓬𝓲𝓸𝓷𝓪𝓻 𝓸𝓼 𝓪𝓽𝓾𝓪𝓲𝓼 𝓼𝓲𝓼𝓽𝓮𝓶𝓪𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮!

𝓞𝓼 𝓭𝓪𝓭𝓸𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓬𝓸𝓶𝓮𝓬̧𝓪𝓻𝓪𝓶 𝓪 𝓽𝓮𝓻 𝓿𝓪𝓵𝓸𝓻 𝓮𝓬𝓸𝓷𝓸́𝓶𝓲𝓬𝓸 𝓮𝓶 𝓽𝓸𝓭𝓸 𝓸 𝓮𝓬𝓸𝓼𝓼𝓲𝓼𝓽𝓮𝓶𝓪 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮, 𝓮𝓼𝓹𝓮𝓬𝓲𝓪𝓵𝓶𝓮𝓷𝓽𝓮 𝓮𝓶 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓮 𝓷𝓪 𝓲𝓷𝓭𝓾́𝓼𝓽𝓻𝓲𝓪 𝓯𝓪𝓻𝓶𝓪𝓬𝓮̂𝓾𝓽𝓲𝓬𝓪, 𝓮 𝓬𝓸𝓶𝓮𝓬̧𝓪𝓻𝓪𝓶 𝓪 𝓼𝓮𝓻 𝓿𝓲𝓼𝓽𝓸𝓼 𝓬𝓸𝓶𝓸 𝓾𝓶𝓪 𝓮𝓼𝓽𝓻𝓪𝓽𝓮́𝓰𝓲𝓪 𝓬𝓸𝓶 𝓹𝓸𝓽𝓮𝓷𝓬𝓲𝓪𝓵. 𝓐 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓽𝓸𝓻𝓷𝓸𝓾-𝓼𝓮 𝓲𝓷𝓽𝓻𝓲𝓰𝓪𝓷𝓽𝓮, 𝓼𝓮𝓷𝓭𝓸 𝓸𝓼 𝓭𝓪𝓭𝓸𝓼 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓸𝓼 𝓶𝓪𝓲𝓸𝓻𝓲𝓽𝓪𝓻𝓲𝓪𝓶𝓮𝓷𝓽𝓮 𝓬𝓸𝓷𝓼𝓲𝓭𝓮𝓻𝓪𝓭𝓸𝓼 𝓹𝓪𝓻𝓪 𝓪𝓳𝓾𝓭𝓪𝓻 𝓪 𝓹𝓻𝓮𝓿𝓮𝓻, 𝓭𝓲𝓪𝓰𝓷𝓸𝓼𝓽𝓲𝓬𝓪𝓻 𝓮 𝓪 𝓽𝓻𝓪𝓽𝓪𝓻 𝓭𝓪 𝓼𝓪𝓾́𝓭𝓮 𝓭𝓮 𝓲𝓷𝓭𝓲𝓿𝓲́𝓭𝓾𝓸𝓼 𝓭𝓮 𝓶𝓸𝓭𝓸 𝓶𝓪𝓲𝓼 𝓹𝓮𝓻𝓼𝓸𝓷𝓪𝓵𝓲𝔃𝓪𝓭𝓸. 𝓔𝓼𝓽𝓻𝓪𝓽𝓮́𝓰𝓲𝓪𝓼 𝓰𝓾𝓲𝓪𝓭𝓪𝓼 𝓹𝓮𝓵𝓪 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓽𝓮̂𝓶 𝓪 𝓬𝓪𝓹𝓪𝓬𝓲𝓭𝓪𝓭𝓮 𝓭𝓮 𝓭𝓲𝓶𝓲𝓷𝓾𝓲𝓻 𝓸 𝓻𝓲𝓼𝓬𝓸 𝓭𝓮 𝓲𝓷𝓬𝓲𝓼𝓪̃𝓸 𝓭𝓮 𝓭𝓸𝓮𝓷𝓬̧𝓪𝓼, 𝓭𝓮 𝓶𝓮𝓵𝓱𝓸𝓻𝓪𝓻 𝓪 𝓪𝓭𝓸𝓬̧𝓪̃𝓸 𝓭𝓮 𝓬𝓸𝓶𝓹𝓸𝓻𝓽𝓪𝓶𝓮𝓷𝓽𝓸𝓼 𝓼𝓪𝓾𝓭𝓪́𝓿𝓮𝓲𝓼, 𝓪𝓼𝓼𝓲𝓶 𝓬𝓸𝓶𝓸 𝓭𝓮 𝓮𝓼𝓹𝓸𝓵𝓮𝓽𝓪𝓻 𝓪 𝓭𝓮𝓽𝓮𝓬̧𝓪̃𝓸 𝓹𝓻𝓮𝓬𝓸𝓬𝓮 𝓭𝓮 𝓭𝓸𝓮𝓷𝓬̧𝓪𝓼 𝓮 𝓸𝓹𝓬̧𝓸̃𝓮𝓼 𝓭𝓮 𝓽𝓻𝓪𝓽𝓪𝓶𝓮𝓷𝓽𝓸 𝓶𝓪𝓲𝓼 𝓭𝓲𝓻𝓮𝓬𝓲𝓸𝓷𝓪𝓭𝓸𝓼. 𝓐 𝓬𝓸𝓵𝓮𝓬̧𝓪̃𝓸 𝓭𝓮 𝓭𝓪𝓭𝓸𝓼 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓸𝓼 𝓮 𝓭𝓮 𝓭𝓪𝓭𝓸𝓼 𝓶𝓪𝓲𝓼 𝓰𝓮𝓻𝓪𝓲𝓼 𝓪 𝓷𝓲́𝓿𝓮𝓵 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓬𝓸𝓶𝓮𝓬̧𝓪𝓻𝓪𝓶 𝓬𝓸𝓶𝓸 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪𝓼 𝓲𝓼𝓸𝓵𝓪𝓭𝓪𝓼, 𝓺𝓾𝓮𝓻 𝓮𝓶 𝓵𝓪𝓫𝓸𝓻𝓪𝓽𝓸́𝓻𝓲𝓸𝓼 𝓱𝓸𝓼𝓹𝓲𝓽𝓪𝓵𝓪𝓻𝓮𝓼, 𝓮𝓶𝓹𝓻𝓮𝓼𝓪𝓼 𝓸𝓾 𝓸𝓾𝓽𝓻𝓸𝓼. 𝓓𝓮 𝓶𝓸𝓶𝓮𝓷𝓽𝓸, 𝓿𝓪́𝓻𝓲𝓸𝓼 𝓹𝓪𝓲́𝓼𝓮𝓼 𝓮𝓼𝓽𝓪̃𝓸 𝓪 𝓮𝓼𝓽𝓪𝓫𝓮𝓵𝓮𝓬𝓮𝓻 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪𝓼 𝓭𝓮 𝓬𝓸𝓵𝓮𝓬̧𝓪̃𝓸 𝓭𝓮 𝓭𝓪𝓭𝓸𝓼 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓲𝓼 𝓹𝓪𝓻𝓪 𝓯𝓾𝓽𝓾𝓻𝓪 𝓲𝓶𝓹𝓵𝓮𝓶𝓮𝓷𝓽𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓶𝓮𝓭𝓲𝓬𝓲𝓷𝓪 𝓹𝓮𝓻𝓼𝓸𝓷𝓪𝓵𝓲𝔃𝓪𝓭𝓪 𝓷𝓸𝓼 𝓼𝓮𝓻𝓿𝓲𝓬̧𝓸𝓼 𝓬𝓵𝓲́𝓷𝓲𝓬𝓸𝓼 𝓭𝓲𝓪́𝓻𝓲𝓸𝓼.

𝓝𝓪𝓼 𝓾́𝓵𝓽𝓲𝓶𝓪𝓼 𝓭𝓾𝓪𝓼 𝓭𝓮́𝓬𝓪𝓭𝓪𝓼 𝓯𝓸𝓻𝓪𝓶 𝓲𝓶𝓹𝓵𝓮𝓶𝓮𝓷𝓽𝓪𝓭𝓸𝓼 𝓹𝓻𝓸𝓳𝓮𝓽𝓸𝓼 𝓭𝓮 𝓰𝓻𝓪𝓷𝓭𝓮 𝓮𝓼𝓬𝓪𝓵𝓪 𝓹𝓸𝓻 𝓽𝓸𝓭𝓪 𝓪 𝓔𝓾𝓻𝓸𝓹𝓪, 𝓬𝓸𝓶𝓸 𝓮́ 𝓸 𝓬𝓪𝓼𝓸 𝓭𝓪 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪 𝓔𝓾𝓻𝓸𝓹𝓮𝓲𝓪 𝓭𝓮 ‘𝟏+ 𝓜𝓲𝓵𝓵𝓲𝓸𝓷 𝓖𝓮𝓷𝓸𝓶𝓮𝓼’, 𝓪 𝓺𝓾𝓪𝓵 𝓬𝓸𝓷𝓼𝓲𝓼𝓽𝓮 𝓷𝓪 𝓬𝓸𝓸𝓹𝓮𝓻𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝟐𝟒 𝓹𝓪𝓲́𝓼𝓮𝓼 𝓮𝓾𝓻𝓸𝓹𝓮𝓾𝓼 𝓹𝓪𝓻𝓪 𝓼𝓮𝓺𝓾𝓮𝓷𝓬𝓲𝓪𝓻 𝓹𝓮𝓵𝓸 𝓶𝓮𝓷𝓸𝓼 𝓾𝓶 𝓶𝓲𝓵𝓱𝓪̃𝓸 𝓭𝓮 𝓰𝓮𝓷𝓸𝓶𝓪𝓼, 𝓬𝓸𝓶 𝓸 𝓲𝓷𝓽𝓾𝓲𝓽𝓸 𝓭𝓮 𝓭𝓲𝓼𝓹𝓸𝓷𝓲𝓫𝓲𝓵𝓲𝔃𝓪𝓻𝓮𝓶 𝓪𝓬𝓮𝓼𝓼𝓸 𝓪̀ 𝓻𝓮𝓼𝓾𝓵𝓽𝓪𝓷𝓽𝓮 𝓫𝓪𝓼𝓮 𝓭𝓮 𝓭𝓪𝓭𝓸𝓼 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓪𝓽𝓮́ 𝟐𝟎𝟐𝟐. 𝓔𝓼𝓽𝓪 𝓬𝓸𝓵𝓮𝓬̧𝓪̃𝓸 𝓽𝓮𝓶 𝓸 𝓹𝓸𝓽𝓮𝓷𝓬𝓲𝓪𝓵 𝓭𝓮 𝓶𝓮𝓵𝓱𝓸𝓻𝓪𝓻 𝓪 𝓹𝓻𝓮𝓿𝓮𝓷𝓬̧𝓪̃𝓸 𝓭𝓮 𝓭𝓸𝓮𝓷𝓬̧𝓪𝓼, 𝓹𝓮𝓻𝓶𝓲𝓽𝓲𝓻 𝓶𝓪𝓲𝓼 𝓽𝓻𝓪𝓽𝓪𝓶𝓮𝓷𝓽𝓸𝓼 𝓹𝓮𝓻𝓼𝓸𝓷𝓪𝓵𝓲𝔃𝓪𝓭𝓸𝓼 𝓮 𝓭𝓮 𝓹𝓻𝓸𝓿𝓲𝓭𝓮𝓷𝓬𝓲𝓪𝓻 𝓲𝓷𝓿𝓮𝓼𝓽𝓲𝓰𝓪𝓬̧𝓪̃𝓸 𝓲𝓷𝓸𝓿𝓪𝓭𝓸𝓻𝓪 𝓬𝓸𝓶 𝓲𝓶𝓹𝓪𝓬𝓽𝓸. 𝓟𝓪𝓻𝓪 𝓪𝓵𝓮́𝓶 𝓭𝓲𝓼𝓼𝓸, 𝓹𝓪𝓲́𝓼𝓮𝓼 𝓮𝓾𝓻𝓸𝓹𝓮𝓾𝓼 𝓬𝓸𝓶𝓸 𝓪 𝓔𝓼𝓽𝓸́𝓷𝓲𝓪 𝓮 𝓸 𝓡𝓮𝓲𝓷𝓸 𝓤𝓷𝓲𝓭𝓸 𝓯𝓸𝓻𝓪𝓶 𝓹𝓲𝓸𝓷𝓮𝓲𝓻𝓸𝓼 𝓷𝓪 𝓬𝓸𝓵𝓮𝓬̧𝓪̃𝓸 𝓮 𝓰𝓮𝓼𝓽𝓪̃𝓸 𝓭𝓮 𝓰𝓻𝓪𝓷𝓭𝓮𝓼 𝓺𝓾𝓪𝓷𝓽𝓲𝓭𝓪𝓭𝓮𝓼 𝓭𝓮 𝓭𝓪𝓭𝓸𝓼 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓸𝓼, 𝓭𝓮 𝓶𝓸𝓭𝓸 𝓪 𝓲𝓶𝓹𝓵𝓮𝓶𝓮𝓷𝓽𝓪𝓻𝓮𝓶 𝓮𝓼𝓯𝓸𝓻𝓬̧𝓸𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓾́𝓫𝓵𝓲𝓬𝓪 𝓶𝓮𝓵𝓱𝓸𝓻𝓪𝓭𝓸𝓼 𝓬𝓸𝓶 𝓯𝓸𝓬𝓸 𝓮𝓶 𝓶𝓮𝓭𝓲𝓭𝓪𝓼 𝓹𝓻𝓮𝓿𝓮𝓷𝓽𝓲𝓿𝓪𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮.

𝓣𝓪𝓲𝓼 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪𝓼 𝓻𝓮𝓺𝓾𝓮𝓻𝓮𝓶 𝓲𝓷𝓯𝓻𝓪𝓮𝓼𝓽𝓻𝓾𝓽𝓾𝓻𝓪𝓼 𝓽𝓮́𝓬𝓷𝓲𝓬𝓪𝓼 𝓪𝓹𝓻𝓸𝓹𝓻𝓲𝓪𝓭𝓪𝓼, 𝓻𝓮𝓺𝓾𝓮𝓻𝓮𝓶 𝓲𝓶𝓹𝓵𝓲𝓬𝓪𝓬̧𝓸̃𝓮𝓼 𝓵𝓮𝓰𝓪𝓲𝓼 𝓮 𝓮́𝓽𝓲𝓬𝓪𝓼 𝓬𝓵𝓪𝓻𝓪𝓼, 𝓪𝓼𝓼𝓲𝓶 𝓬𝓸𝓶𝓸 𝓪 𝓮𝓭𝓾𝓬𝓪𝓬̧𝓪̃𝓸 𝓼𝓸𝓫𝓻𝓮 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓭𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬̧𝓪̃𝓸 𝓮 𝓭𝓸𝓼 𝓭𝓮𝓬𝓲𝓼𝓸𝓻𝓮𝓼 𝓹𝓸𝓵𝓲́𝓽𝓲𝓬𝓸𝓼 𝓪 𝓯𝓲𝓶 𝓭𝓮 𝓰𝓪𝓻𝓪𝓷𝓽𝓲𝓻 𝓪 𝓼𝓾𝓪 𝓪𝓬𝓮𝓲𝓽𝓪𝓬̧𝓪̃𝓸 𝓹𝓮𝓵𝓸𝓼 𝓼𝓲𝓼𝓽𝓮𝓶𝓪𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓮 𝓲𝓷𝓽𝓮𝓰𝓻𝓪𝓬̧𝓪̃𝓸 𝓮𝓶 𝓬𝓾𝓲𝓭𝓪𝓭𝓸𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓮𝓻𝓼𝓸𝓷𝓪𝓵𝓲𝔃𝓪𝓭𝓸𝓼. 𝓐 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓭𝓪́ 𝓸𝓹𝓸𝓻𝓽𝓾𝓷𝓲𝓭𝓪𝓭𝓮 𝓭𝓮 𝓭𝓮𝓼𝓮𝓷𝓿𝓸𝓵𝓿𝓮𝓻 𝓶𝓮𝓭𝓲𝓬𝓪𝓶𝓮𝓷𝓽𝓸𝓼, 𝓽𝓮𝓻𝓪𝓹𝓲𝓪𝓼 𝓮 𝓲𝓷𝓽𝓮𝓻𝓿𝓮𝓷𝓬̧𝓸̃𝓮𝓼 𝓶𝓪𝓲𝓼 𝓹𝓮𝓻𝓼𝓸𝓷𝓪𝓵𝓲𝔃𝓪𝓭𝓸𝓼 𝓮 𝓶𝓪𝓲𝓼 𝓭𝓲𝓻𝓮𝓬𝓲𝓸𝓷𝓪𝓭𝓸𝓼. 𝓟𝓪𝓻𝓪 𝓪𝓵𝓮́𝓶 𝓭𝓲𝓼𝓼𝓸, 𝓹𝓸𝓭𝓮 𝓽𝓪𝓶𝓫𝓮́𝓶 𝓪𝓫𝓻𝓲𝓻 𝓹𝓸𝓻𝓽𝓪𝓼 𝓹𝓪𝓻𝓪 𝓶𝓮𝓵𝓱𝓸𝓻𝓮𝓼 𝓭𝓲𝓪𝓰𝓷𝓸́𝓼𝓽𝓲𝓬𝓸𝓼, 𝓲𝓶𝓹𝓾𝓵𝓼𝓲𝓸𝓷𝓪𝓻 𝓪 𝓹𝓻𝓮𝓿𝓮𝓷𝓬̧𝓪̃𝓸 𝓮 𝓯𝓪𝔃𝓮𝓻 𝓾𝓼𝓸 𝓭𝓸𝓼 𝓻𝓮𝓬𝓾𝓻𝓼𝓸𝓼 𝓮𝔁𝓲𝓼𝓽𝓮𝓷𝓽𝓮𝓼 𝓭𝓮 𝓶𝓸𝓭𝓸 𝓶𝓪𝓲𝓼 𝓮𝓯𝓲𝓬𝓲𝓮𝓷𝓽𝓮. 𝓓𝓮𝓼𝓭𝓮 𝓸 𝓬𝓪𝓷𝓬𝓻𝓸 𝓪 𝓭𝓸𝓮𝓷𝓬̧𝓪𝓼 𝓻𝓪𝓻𝓪𝓼, 𝓪 𝓭𝓸𝓮𝓷𝓬̧𝓪𝓼 𝓷𝓮𝓾𝓻𝓸𝓵𝓸́𝓰𝓲𝓬𝓪𝓼, 𝓪 𝓷𝓸𝓿𝓸𝓼 𝓼𝓾𝓻𝓽𝓸𝓼 𝓮 𝓹𝓻𝓮𝓿𝓮𝓷𝓬̧𝓪̃𝓸, 𝓪 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓹𝓸𝓭𝓮 𝓶𝓮𝓵𝓱𝓸𝓻𝓪𝓻 𝓲𝓶𝓮𝓷𝓼𝓪𝓶𝓮𝓷𝓽𝓮 𝓪 𝓼𝓪𝓾́𝓭𝓮 𝓭𝓸𝓼 𝓬𝓲𝓭𝓪𝓭𝓪̃𝓸𝓼. 𝓐 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓪 𝓽𝓮𝓶 𝓸 𝓹𝓸𝓽𝓮𝓷𝓬𝓲𝓪𝓵 𝓭𝓮 𝓶𝓮𝓵𝓱𝓸𝓻𝓪𝓻 𝓪 𝓮𝓯𝓲𝓬𝓲𝓮̂𝓷𝓬𝓲𝓪, 𝓪𝓬𝓮𝓼𝓼𝓲𝓫𝓲𝓵𝓲𝓭𝓪𝓭𝓮, 𝓼𝓾𝓼𝓽𝓮𝓷𝓽𝓪𝓫𝓲𝓵𝓲𝓭𝓪𝓭𝓮 𝓮 𝓻𝓮𝓼𝓲𝓵𝓲𝓮̂𝓷𝓬𝓲𝓪 𝓭𝓸𝓼 𝓼𝓲𝓼𝓽𝓮𝓶𝓪𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮.

𝓒𝓸𝓷𝓼𝓮𝓺𝓾𝓮𝓷𝓽𝓮𝓶𝓮𝓷𝓽𝓮, 𝓮́ 𝓷𝓮𝓬𝓮𝓼𝓼𝓪́𝓻𝓲𝓸 𝓱𝓪𝓿𝓮𝓻 𝓾𝓶𝓪 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪 𝓭𝓮 𝓬𝓸𝓵𝓮𝓬̧𝓪̃𝓸 𝓮 𝓪𝓰𝓻𝓮𝓰𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓭𝓪𝓭𝓸𝓼 𝓰𝓮𝓷𝓮́𝓽𝓲𝓬𝓸𝓼 𝓪 𝓷𝓲́𝓿𝓮𝓵 𝓷𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓮𝓶 𝓟𝓸𝓻𝓽𝓾𝓰𝓪𝓵. 𝓣𝓪𝓵 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪 𝓷𝓪̃𝓸 𝓼𝓸́ 𝓲𝓷𝓬𝓮𝓷𝓽𝓲𝓿𝓪𝓻𝓲𝓪 𝓪 𝓲𝓷𝓿𝓮𝓼𝓽𝓲𝓰𝓪𝓬̧𝓪̃𝓸 𝓲𝓷𝓸𝓿𝓪𝓭𝓸𝓻𝓪, 𝓬𝓸𝓶𝓸 𝓽𝓪𝓶𝓫𝓮́𝓶 𝓹𝓻𝓸𝓶𝓸𝓿𝓮𝓻𝓲𝓪 𝓲𝓷𝓸𝓿𝓪𝓬̧𝓪̃𝓸 𝓷𝓪 𝓲𝓷𝓭𝓾́𝓼𝓽𝓻𝓲𝓪 𝓯𝓪𝓻𝓶𝓪𝓬𝓮̂𝓾𝓽𝓲𝓬𝓪. 𝓟𝓪𝓻𝓪 𝓪𝓵𝓮́𝓶 𝓭𝓮 𝓺𝓾𝓮 𝓹𝓸𝓼𝓼𝓲𝓫𝓲𝓵𝓲𝓽𝓪𝓻𝓲𝓪 𝓬𝓸𝓸𝓻𝓭𝓮𝓷𝓪𝓻 𝓮𝓼𝓽𝓻𝓪𝓽𝓮́𝓰𝓲𝓪𝓼 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓾́𝓫𝓵𝓲𝓬𝓪 𝓬𝓸𝓷𝓯𝓸𝓻𝓶𝓮 𝓸𝓼 𝓻𝓲𝓼𝓬𝓸𝓼 𝓲𝓭𝓮𝓷𝓽𝓲𝓯𝓲𝓬𝓪𝓭𝓸𝓼 𝓷𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬̧𝓪̃𝓸 𝓮 𝓪𝓭𝓪𝓹𝓽𝓪𝓻 𝓪 𝓮𝓭𝓾𝓬𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓹𝓻𝓸𝓯𝓲𝓼𝓼𝓲𝓸𝓷𝓪𝓲𝓼 𝓹𝓪𝓻𝓪 𝓸𝓼 𝓪𝓷𝓸𝓼 𝓯𝓾𝓽𝓾𝓻𝓸𝓼 𝓬𝓸𝓶 𝓮𝓼𝓼𝓮 𝓶𝓮𝓼𝓶𝓸 𝓹𝓻𝓸𝓹𝓸́𝓼𝓲𝓽𝓸. 𝓞 𝓹𝓮𝓻𝓬𝓾𝓻𝓼𝓸 𝓭𝓸 𝓼𝓲𝓼𝓽𝓮𝓶𝓪 𝓷𝓪𝓬𝓲𝓸𝓷𝓪𝓵 𝓭𝓮 𝓼𝓪𝓾́𝓭𝓮 𝓹𝓸𝓻𝓽𝓾𝓰𝓾𝓮̂𝓼 𝓶𝓸𝓼𝓽𝓻𝓪 𝓺𝓾𝓮 𝓮́ 𝓹𝓸𝓼𝓼𝓲́𝓿𝓮𝓵 𝓪𝓵𝓬𝓪𝓷𝓬̧𝓪𝓻 𝓽𝓪𝓵 𝓲𝓷𝓲𝓬𝓲𝓪𝓽𝓲𝓿𝓪 𝓪 𝓷𝓲́𝓿𝓮𝓵 𝓹𝓸𝓹𝓾𝓵𝓪𝓬𝓲𝓸𝓷𝓪𝓵, 𝓮𝓼𝓹𝓮𝓬𝓲𝓪𝓵𝓶𝓮𝓷𝓽𝓮 𝓬𝓸𝓶 𝓸𝓼 𝓮𝓼𝓯𝓸𝓻𝓬̧𝓸𝓼 𝓪 𝓭𝓮𝓬𝓸𝓻𝓻𝓮𝓻𝓮𝓶 𝓬𝓸𝓶 𝓪 𝓲𝓶𝓹𝓵𝓮𝓶𝓮𝓷𝓽𝓪𝓬̧𝓪̃𝓸 𝓭𝓸 𝓟𝓵𝓪𝓷𝓸 𝓭𝓮 𝓡𝓮𝓬𝓾𝓹𝓮𝓻𝓪𝓬̧𝓪̃𝓸 𝓮 𝓡𝓮𝓼𝓲𝓵𝓲𝓮̂𝓷𝓬𝓲𝓪 𝓮𝓶 𝓿𝓲𝓼𝓽𝓪 𝓹𝓪𝓻𝓪 𝟐𝟎𝟐𝟏-𝟐𝟎𝟐𝟔. 𝓓𝓮𝓿𝓮𝓶𝓸𝓼 𝓾𝓼𝓪𝓻 𝓪 𝓬𝓻𝓲𝓼𝓮 𝓹𝓪𝓷𝓭𝓮́𝓶𝓲𝓬𝓪 𝓪𝓽𝓾𝓪𝓵 𝓹𝓪𝓻𝓪 𝓪𝓫𝓻𝓪𝓬̧𝓪𝓻 𝓪 𝓽𝓻𝓪𝓷𝓼𝓯𝓸𝓻𝓶𝓪𝓬̧𝓪̃𝓸 𝓭𝓪 𝓼𝓪𝓾́𝓭𝓮 𝓮 𝓬𝓸𝓵𝓸𝓬𝓪𝓻 𝓟𝓸𝓻𝓽𝓾𝓰𝓪𝓵 𝓷𝓪 𝓯𝓻𝓮𝓷𝓽𝓮 𝓭𝓪 𝓲𝓷𝓸𝓿𝓪𝓬̧𝓪̃𝓸 𝓮𝓶 𝓼𝓪𝓾́𝓭𝓮 𝓪 𝓷𝓲́𝓿𝓮𝓵 𝓮𝓾𝓻𝓸𝓹𝓮𝓾. 𝓜𝓪𝓲𝓼 𝓬𝓻𝓲𝓼𝓮𝓼 𝓿𝓲𝓻𝓪̃𝓸 𝓮 𝓿𝓪𝓶𝓸𝓼 𝓺𝓾𝓮𝓻𝓮𝓻 𝓮𝓼𝓽𝓪𝓻 𝓶𝓪𝓲𝓼 𝓹𝓻𝓮𝓹𝓪𝓻𝓪𝓭𝓸𝓼, 𝓷𝓪̃𝓸 𝓼𝓸́ 𝓷𝓪 𝓲𝓶𝓹𝓵𝓮𝓶𝓮𝓷𝓽𝓪𝓬̧𝓪̃𝓸 𝓭𝓮 𝓼𝓸𝓵𝓾𝓬̧𝓸̃𝓮𝓼 𝓭𝓲𝓰𝓲𝓽𝓪𝓲𝓼 𝓮 𝓮𝓺𝓾𝓲𝓹𝓪𝓶𝓮𝓷𝓽𝓸𝓼 𝓲𝓷𝓸𝓿𝓪𝓭𝓸𝓻𝓮𝓼 𝓮𝓶 𝓼𝓪𝓾́𝓭𝓮, 𝓶𝓪𝓼 𝓹𝓻𝓲𝓷𝓬𝓲𝓹𝓪𝓵𝓶𝓮𝓷𝓽𝓮 𝓷𝓪 𝓹𝓻𝓮𝓿𝓮𝓷𝓬̧𝓪̃𝓸 𝓭𝓸 𝓻𝓲𝓼𝓬𝓸 𝓭𝓮 𝓽𝓸𝓭𝓪 𝓪 𝓹𝓸𝓹𝓾𝓵𝓪𝓬̧𝓪̃𝓸.

* 30 anos, é Engenheira Biomédica com mestrado em Empreendedorismo e Inovação em Saúde. Trabalha atualmente na Beta-i, consultora de inovação, como Senior Account Manager, promovendo inovação de soluções digitais em Saúde em todo o ecossistema. Para além disso, a Maria contribui para o grupo de trabalho do projeto Moving Genomics to the Clinic, do World Economic Forum. Ao frequentar o programa de doutoramento do MIT Portugal, a Maria focou-se nos desafios da utilização e partilha de dados genéticos. Os seus interesses em eHealth, medicina personalizada, genética, nutrição e inovação levaram-na às Nações Unidas, ao MIT, para além de startups. Juntou-se aos Global Shapers Lisbon Hub no final de 2019.

IN "OBSERVADOR" - 20/04/21

.